$636.73 Million in Sales Expected for Teleflex Incorporated (TFX) This Quarter

Analysts expect Teleflex Incorporated (NYSE:TFX) to announce sales of $636.73 million for the current quarter, according to Zacks. Six analysts have made estimates for Teleflex’s earnings, with the highest sales estimate coming in at $637.50 million and the lowest estimate coming in at $635.20 million. Teleflex posted sales of $609.87 million during the same quarter last year, which suggests a positive year over year growth rate of 4.4%. The business is scheduled to issue its next quarterly earnings results on Thursday, August 1st.

According to Zacks, analysts expect that Teleflex will report full-year sales of $2.58 billion for the current financial year, with estimates ranging from $2.58 billion to $2.59 billion. For the next fiscal year, analysts anticipate that the company will post sales of $2.76 billion, with estimates ranging from $2.75 billion to $2.79 billion. Zacks’ sales calculations are an average based on a survey of analysts that follow Teleflex.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, May 2nd. The medical technology company reported $2.24 EPS for the quarter, beating the consensus estimate of $2.17 by $0.07. Teleflex had a return on equity of 18.62% and a net margin of 7.50%. The firm had revenue of $613.60 million during the quarter, compared to analysts’ expectations of $608.27 million. During the same period in the prior year, the firm posted $2.15 earnings per share. The business’s quarterly revenue was up 4.5% compared to the same quarter last year.

TFX has been the subject of several recent research reports. Zacks Investment Research raised Teleflex from a “hold” rating to a “buy” rating and set a $338.00 price target for the company in a research report on Friday, May 10th. Needham & Company LLC reissued a “strong-buy” rating and set a $325.00 price target (up from $300.00) on shares of Teleflex in a research report on Friday, February 22nd. Morgan Stanley increased their price target on Teleflex from $305.00 to $315.00 and gave the company an “overweight” rating in a research report on Tuesday, February 26th. Barclays set a $287.00 price target on Teleflex and gave the company a “hold” rating in a research report on Friday, February 22nd. Finally, UBS Group increased their price target on Teleflex to $350.00 and gave the company a “buy” rating in a research report on Friday, March 22nd. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $327.86.

In other Teleflex news, VP John Deren sold 125 shares of Teleflex stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $290.43, for a total transaction of $36,303.75. Following the transaction, the vice president now directly owns 2,539 shares of the company’s stock, valued at approximately $737,401.77. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Benson Smith sold 8,500 shares of Teleflex stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $300.15, for a total value of $2,551,275.00. Following the transaction, the director now directly owns 84,913 shares in the company, valued at $25,486,636.95. The disclosure for this sale can be found here. In the last three months, insiders have sold 48,525 shares of company stock worth $14,434,194. 2.36% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Oppenheimer Asset Management Inc. lifted its holdings in shares of Teleflex by 15.8% during the 4th quarter. Oppenheimer Asset Management Inc. now owns 3,459 shares of the medical technology company’s stock valued at $894,000 after buying an additional 472 shares during the last quarter. Exane Derivatives acquired a new stake in Teleflex in the 4th quarter worth approximately $41,000. Rhumbline Advisers lifted its holdings in Teleflex by 38.6% in the 4th quarter. Rhumbline Advisers now owns 128,957 shares of the medical technology company’s stock worth $33,333,000 after purchasing an additional 35,912 shares during the last quarter. First Mercantile Trust Co. lifted its holdings in Teleflex by 83.1% in the 4th quarter. First Mercantile Trust Co. now owns 1,267 shares of the medical technology company’s stock worth $327,000 after purchasing an additional 575 shares during the last quarter. Finally, Dupont Capital Management Corp lifted its holdings in Teleflex by 865.7% in the 4th quarter. Dupont Capital Management Corp now owns 5,794 shares of the medical technology company’s stock worth $1,498,000 after purchasing an additional 5,194 shares during the last quarter. 91.52% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE TFX opened at $301.76 on Friday. Teleflex has a 52 week low of $226.02 and a 52 week high of $309.99. The company has a quick ratio of 1.41, a current ratio of 2.27 and a debt-to-equity ratio of 0.85. The company has a market cap of $13.52 billion, a P/E ratio of 30.48, a P/E/G ratio of 1.96 and a beta of 0.94.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Wednesday, May 15th will be issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 0.45%. The ex-dividend date is Tuesday, May 14th. Teleflex’s dividend payout ratio (DPR) is 13.74%.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Recommended Story: Tariff

Get a free copy of the Zacks research report on Teleflex (TFX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.